

NIH Public Access

Author Manuscript

Int J Cancer. Author manuscript; available in PMC 2010 August 15

Published in final edited form as:

Int J Cancer. 2009 August 15; 125(4): 909–917. doi:10.1002/ijc.24327.

Genetic variants in pigmentation genes, pigmentary phenotypes, and risk of skin cancer in Caucasians

Hongmei Nan^{1,2,*}, Peter Kraft¹, David J. Hunter^{1,2}, and Jiali Han^{1,2}

1 Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Harvard School of Public Health, Boston, MA

2 Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

Abstract

Human pigmentation is a polygenic quantitative trait with high heritability. Although a large number of single nucleotide polymorphisms (SNPs) have been identified in pigmentation genes, very few SNPs have been examined in relation to human pigmentary phenotypes and skin cancer risk. We evaluated the associations between fifteen SNPs in eight candidate pigmentation genes (TYR, TYRP1, OCA2, SLC24A5, SLC45A2, POMC, ASIP, and ATRN) and both pigmentary phenotypes (hair color, skin color, and tanning ability) and skin cancer risk in a nested case-control study of Caucasians within the Nurses' Health Study (NHS) among 218 melanoma cases, 285 squamous cell carcinoma (SCC) cases, 300 basal cell carcinoma (BCC) cases, and 870 common controls. We found that the TYR Arg402Gln variant was significantly associated with skin color (p-value $= 7.7 \times 10^{-4}$) and tanning ability (p-value = 7.3×10^{-4}); the SLC45A2 Phe374Leu variant was significantly associated with hair color (black to blonde) (p-value = 2.4×10^{-7}), skin color (p-value = 1.1×10^{-7}), and tanning ability (p-value) value = 2.5×10^{-4}). These associations remained significant after controlling for *MC1R* variants. No significant associations were found between these polymorphisms and the risk of skin cancer. We observed that the TYRP1 rs1408799 and SLC45A2 -1721 C>G were associated with melanoma risk (OR, 0.77; 95% CI, 0.60–0.98 and OR, 0.75; 95% CI, 0.60–0.95, respectively). The TYR Ser192Tyr was associated with SCC risk (OR, 1.23; 95% CI, 1.00–1.50). The TYR haplotype carrying only the Arg402Gln variant allele was significantly associated with SCC risk (OR, 1.35; 95% CI, 1.04–1.74). The OCA2 Arg419Gln and ASIP g.8818 A>G were associated with BCC risk (OR, 1.50; 95% CI, 1.06-2.13 and OR, 0.73; 95% CI, 0.53-1.00, respectively). The haplotype near ASIP (rs4911414[T] and rs1015362[G]) was significantly associated with fair skin color (OR, 2.28; 95% CI, 1.46-3.57) as well as the risks of melanoma (OR, 1.68; 95% CI, 1.18–2.39) and SCC (OR, 1.54; 95% CI, 1.08– 2.19). These associations remained similar after adjusting for pigmentary phenotypes and MCIR variants. The statistical power of this study was modest and additional studies are warranted to confirm the associations observed in the present study. This study provides evidence for the contribution of pigmentation genetic variants, in addition to the MC1R variants, to variation in human pigmentary phenotypes and possibly the development of skin cancer.

Keywords

SNPs; pigmentation gene; pigmentary phenotypes; skin cancer

^{*}Correspondence to: Hongmei Nan, Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Harvard School of Public Health, 677 Huntington Ave, Boston, MA 02115, USA. Telephone: +617-432-5896. Fax: 617-432-1722. E-mail: E-mail: hnan@hsph.harvard.edu.

Introduction

Human pigmentation shows substantial variation both within and among human populations, with high heritability ^{1, 2}. Ultraviolet (UV) exposure is one of the most important environmental variables partially influencing evolutionary selective pressure on human pigmentation ³. Melanin synthesized within melanosomes in melanocyte is the main contributor to human pigmentation. There are two main types of melanin: pheomelanin (red or yellow) and eumelanin (black or brown) ⁴.

It has been hypothesized that human pigmentation is tightly regulated by multiple pigmentation genes harboring a handful of genetic variants (Figure 1). The genes involved in the process of pigmentation, such as formation, transport, and distribution of melanosome, have been identified through animal models ⁵. Melanin production is initiated by α -melanocytestimulating hormone (α -MSH), which is produced by proteolysis from a multicomponent precursor polypeptide encoded by the pro-opiomelanocortin (POMC) gene ⁶. A previously well-documented pigmentation gene, MCIR (melanocortin 1 receptor), encodes a 317-amino acid 7-pass transmembrane G-protein coupled receptor. As an agonist of MCIR, the induced POMC/ α -MSH binds to *MC1R*, leading to elevated cAMP levels and resulting in eumelanin production ^{7, 8}. Alternatively, the agouti signaling protein (ASIP) can also bind to the MC1R, blocking the MC1R-stimulated elevation of cAMP, and over-expression of ASIP produces a yellow coat color in mice 5, 9, 10. Attractin encoded by the *ATRN* gene is a lowaffinity receptor for the ASIP protein product. A recessive color mutation mahogany (Atrn^{mg}) was recognized as a modifier of agouti coat color in mice ^{11, 12}. Tyrosinase (TYR) is required for melanization in both types of melanosome, whereas the tyrosinase-related protein 1 (*TYRP1*) is exclusive to the melanization of eumelanosome 13, 14. Hence, tyrosinase is a critical enzyme during melanosomal maturation and its high activity leads to the formation of eumelanosome ^{15, 16}. The optimal activity of tyrosinase in human melanocytes requires an appropriate ionic environment, which is partially controlled by P-protein functioning as a pH exchange membrane channel ^{17, 18}. The twelve transmembrane-spanning P-protein encoded by the OCA2 gene (human type II oculocutaneous albinism-related gene) was discovered in the "pink-eyed dilution" mouse mutant ¹⁹. In addition to P-protein, MATP, a membraneassociated transporter protein encoded by the SLC45A2 gene, has been considered as a sodiumhydrogen exchanger of melanosomes, regulating tyrosinase activity in human melanocyte 20 . Another cation exchanger, *SLC24A5*, transports calcium or potassium ions into the melanosome and is involved in melanogenesis. It has been proposed that the human *SLC24A5* gene is required for maturation of melanosome and has a role in skin pigmentation 21, 22

Lighter pigmentation is the host susceptibility risk factor for skin cancer ²³. Although a large number of single nucleotide polymorphisms (SNPs) were identified in pigmentation genes, very few SNPs have been examined in relation to human pigmentary phenotypes and skin cancer risk. Recent genome-wide association studies on pigmentary traits and skin cancer risks (melanoma and basal cell carcinoma) have generated additional information on both pigmentary phenotype related- and skin cancer related-genetic variants ^{24–28}. In the present study, we evaluated the associations of fifteen SNPs in eight candidate pigmentary phenotypes (hair color, skin color, and tanning ability) and the risk of melanoma and non-melanoma skin cancer (squamous cell carcinoma (SCC) and basal cell carcinoma (BCC)) in a nested case-control study within the Nurses' Health Study (NHS).

Page 2

Materials and Methods

Study population

The NHS was established in 1976, when 121,700 female registered nurses between the ages of 30 and 55, residing in 11 larger U.S. states, completed and returned the initial selfadministered questionnaire on their medical histories and baseline health-related exposures, forming the basis for the NHS cohort. Updated information has been obtained by questionnaires every two years. From May 1989 through September 1990, we collected blood samples from 32,826 participants in the NHS cohort. The distributions of risk factors for skin cancer were very similar in the subcohort of those who donated blood samples as in the overall cohort ²⁹. Eligible cases in this study consisted of women with incident skin cancer from the subcohort who had given a blood specimen, including SCC and BCC cases with a diagnosis anytime after blood collection up to June 1, 1998 and melanoma cases up to June 1, 2000 that had no previously diagnosed skin cancer. All available pathologically confirmed melanoma and SCC cases and 300 self-reported BCC cases randomly selected from ~2,600 available self-reported BCC cases were included. The validity of self-report of BCC is high in this medically sophisticated population (90%) $^{30, 31}$. A common control series was randomly selected from participants who gave a blood sample and were free of diagnosed skin cancer up to and including the questionnaire cycle in which the case was diagnosed. One or two controls were matched to each case by year of birth $(\pm 1 \text{ year})$. All subjects were the U.S. non-Hispanic Caucasian women in this study. The nested case-control study consisted of 218 melanoma cases, 285 SCC cases, a sample of 300 BCC cases from the large number of incident cases, and 870 matched controls. The study protocol was approved by the Committee on Use of Human Subjects of the Brigham and Women's Hospital, Boston, MA.

Exposure data

We obtained information regarding skin cancer risk factors from the prospective biennial questionnaires and a retrospective supplementary questionnaire. Information on natural hair color at age 20 and childhood and adolescent tanning tendency were collected in the 1982 prospective questionnaire into five categories (black, dark brown, light brown, blonde, and red) and four categories (practically none, light tan, average tan, and deep tan), respectively. Question on ethnic group was ascertained in the 1992 questionnaire. In the skin cancer nested case-control study, natural skin color and other sun exposure-related information were collected by the retrospective supplementary questionnaire in 2002. The response rate of cases and controls were 92% and 89%, respectively. Information on natural skin color was classified into three categories (fair, medium, and olive). In addition, the eleven states of residence of cohort members at baseline were grouped into three regions: Northeast (Connecticut, Massachusetts, Maryland, New Jersey, New York, and Pennsylvania), Northcentral (Michigan and Ohio), and West and South (California, Texas, and Florida).

Laboratory assays

We genotyped fifteen SNPs in eight candidate pigmentation genes (*TYR*, *TYRP1*, *OCA2*, *SLC24A5*, *SLC45A2*, *POMC*, *ASIP*, and *ATRN*) using the OpenArrayTM SNP Genotyping System (BioTrove, Woburn, MA). Due to the assay failed we genotyped rs1393350 as a surrogate for the *TYR* Arg402Gln (rs1126809) (D'=1 and r²=0.86)

(http://snp500cancer.nci.nih.gov). Laboratory personnel were blinded to the case-control status, and 42 blinded quality control samples were inserted to validate genotyping procedures; concordance for the blinded samples was 100%. Primers, probes, and conditions for genotyping assays are available upon request. The genotyping method for the *MC1R* variants was described previously ²⁹.

Statistical methods

We used the χ^2 test to assess whether the genotypes for all fifteen SNPs were in Hardy-Weinberg equilibrium among the controls.

The MCIR gene has been strongly associated with human pigmentary phenotypes, especially with red hair color 32-34. We previously reported the frequency distribution of seven common MC1R variants among controls, including three "red hair color" (RHC) variants (Arg151Cys, Arg160Trp, and Asp294His) and four "non-red hair color" (NRHC) variants (Val60Leu, Val92Met, Ile155Thr, and Arg163Gln)²⁹. In order to compare the contribution of these fifteen SNPs to pigmentary phenotypes with that of the MC1R variants, we evaluated the associations between the MC1R variants and pigmentary phenotypes in parallel. We regressed an ordinal coding for skin color (1=fair; 2=medium; and 3=olive) or tanning ability (1=practically none; 2=light tan; 3=average tan; and 4=deep tan) on an ordinal coding for genotype (0, 1, or 2 copies of SNP minor allele). For hair color, we used two different statistical models: A) we tested the association between the ordinal genotype coding and an ordinal coding of hair color excluding the women with red hair (1=black; 2=dark brown; 3=light brown; and 4=blonde) using linear regression; and B) we used logistic regression to test the association between the ordinal genotype coding and a binary red hair phenotype (red hair vs. non-red hair color). For the SLC45A2 Gln272Lys and three MC1R NRHC variants (Val92Met, Ile155Thr, and Arg163Gln), we used Fisher's exact test for "red vs. non-red hair color" analysis because none of the women with red hair color carried the variant allele.

We evaluated the association between each genotype and skin cancer risk using unconditional logistic regression. We compared each type of skin cancer with the common control series to increase the statistical power.

In the haplotype analysis, haplotype frequencies and expected haplotype counts for each individual were estimated using a simple expectation-maximization algorithm, as implemented in SAS PROC HAPLOTYPE. The association analyses between haplotypes and binary pigmentary phenotypes and skin cancer risk were performed using the expectation-substitution technique ³⁵. All statistical analyses were two-sided and carried out using SAS V9.1 (SAS Institute, Cary, NC).

Results

Descriptive characteristics of cases and controls

At the beginning of the follow-up of this nested case-control study, the women were between 43 and 68 years old with a mean age of 58.7. The mean age at diagnosis of melanoma cases was 63.4 and that of SCC and BCC cases was 64.7 and 64.0, respectively. Basic characteristics of cases and controls in this study are presented in Table 1. Detailed description and statistical tests were published previously ²³. Briefly, skin cancer cases were more likely to possess red hair color and fair skin color. The childhood tanning ability of cases was less than that of controls. Women in the West and South regions were more likely to be diagnosed with SCC or BCC compared with those in Northeast. A family history of skin cancer was a risk factor for the three types of skin cancer. Those with skin cancers were more likely to have used sunlamps or attended tanning salons. Those with skin cancers had higher cumulative sun exposure while wearing a bathing suit and more lifetime severe sunburns that blistered.

Association between the fifteen SNPs in pigmentation genes and pigmentary phenotypes

Information on the fifteen SNPs in pigmentation genes is presented in Table 2. We selected putative functional SNPs in the 6 pigmentation genes (*TYR*, *OCA2*, *SLC45A2*, *POMC*, *ASIP*, and *ATRN*), including non-synonymous SNPs and those in the promoter and UTR regions. For

the *SLC24A5* gene, the Ala111Thr (rs1426654) is monomorphic in HapMap CEU samples. The SNP rs17426596 is the only one with minor allele frequency >1% in the HapMap CEU samples. Recently, an eye-color variant in *TYRP1* (rs1408799) was reported to be associated with melanoma risk ²⁵, ²⁷. A haplotype near *ASIP* carrying rs4911414 variant allele[T] and rs1015362 major allele[G] (hereafter called *ASIP* AH) was associated with pigmentary phenotypes (skin sensitivity to sun, burn, and freckle) as well as the risks of melanoma and BCC ²⁵, ²⁷. These three SNPs were evaluated for the association with pigmentary phenotypes and the risk of skin cancer as well in this study. The distributions of genotypes for these fifteen SNPs were in Hardy-Weinberg equilibrium among controls. The participants of this study were from 11 states, which were grouped into three regions (Northeast, Northcentral, and West and South). The minor allele frequencies of the fifteen genetic variants according to the 11 individual states are presented in Supplementary Table 1. There were no significant differences in minor allele frequencies of these fifteen SNPs across the 11 states (all *p*-values>0.05).

We evaluated the associations between the fifteen SNPs and pigmentary phenotypes including hair color, skin color, and tanning ability among controls (Table 3). We observed significant associations between *SLC45A2* Phe374Leu (*p*-value = 2.4×10^{-7}) and *SLC45A2* Glu272Lys (*p*-value = 6.0×10^{-5}), and hair color (black to blonde). We then mutually adjusted these two significant *SLC45A2* SNPs and found that only the *SLC45A2* Phe374Leu remained significant. The *p*-value for *SLC45A2* Phe374Leu and *SLC45A2* Glu272Lys was 8.0×10^{-4} and 0.15, respectively. The *SLC45A2* Phe374Leu remained significantly associated with hair color after adjusting for *MC1R* variants (*p*-value = 3.3×10^{-6}) (Supplementary Table 2a and 2b). However, in the analysis of "red hair vs. non-red hair color", there was no significant association between any of the fifteen polymorphisms and red hair color (Table 3). In contrast, the three *MC1R* RHC variants were significantly associated with red hair color phenotype.

We found that the *TYR* Arg402Gln and *SLC45A2* Phe374Leu were significantly associated with skin color (*p*-value = 7.7×10^{-4} and 1.1×10^{-7} , respectively) and tanning ability (*p*-value = 7.3×10^{-4} and 2.5×10^{-4} , respectively). The *OCA2* Arg305Trp was associated with skin color (*p*-value=0.04). These associations remained significant after controlling for the *MC1R* variants (Table 3, Supplementary Table 2a and 2b). The significant associations between the *SLC45A2* Glu272Lys and skin color and tanning ability were eliminated after controlling for the *SLC45A2* Phe374Leu (*p*-value =0.97 and 0.49, respectively).

We found a significant association of ASIP G>T (rs4911414) polymorphism with skin color and tanning ability (*p*-value =1.4×10⁻³ and 0.02, respectively). However, the association with tanning ability was eliminated after adjusting for the *MC1R* variants (*p*-value =0.19), while the association with skin color remained significant (*p*-value =0.01) (Table 3, Supplementary Table 2a and 2b). We also performed a global test to evaluate whether the haplotype frequencies were different between various pigmentary phenotypes (Supplementary Table 3). Consistent with the single SNP analysis of *ASIP* G>T (rs4911414), the haplotype *ASIP* AH was significantly associated with fair skin color (OR, 2.28; 95% CI, 1.46–3.57) (*p*-value for global test, 0.003). This association remained significant after adjusting for the *ASIP* g.8818 A>G (OR, 2.54; 95% CI, 1.58–4.07).

All the significant associations described above with pigmentary phenotypes remained significant after controlling for the geographic regions (either by 11 states or 3 combined groups) (data not shown).

Association between the fifteen SNPs in pigmentation genes and skin cancer risk

The main effect of each polymorphism was evaluated across the three types of skin cancer (Table 4). In the analyses controlling for age, we observed that the *TYRP1* rs1408799 and *SLC45A2* -1721 C>G were associated with melanoma risk (OR, 0.77; 95% CI, 0.60–0.98 and

OR, 0.75; 95% CI, 0.60–0.95, respectively); the *TYR* Ser192Tyr and *ASIP* rs4911414 were associated with SCC risk (OR, 1.23; 95% CI, 1.00–1.50 and OR, 1.29; 95% CI, 1.05–1.59, respectively); the *OCA2* Arg419Gln and *ASIP* g.8818 A>G were associated with BCC risk (OR, 1.50; 95% CI, 1.06–2.13 and OR, 0.73; 95% CI, 0.53–1.00, respectively). These associations remained similar after adjusting for either pigmentary phenotypes (hair color, skin color, and tanning ability) (Supplementary Table 4) or *MC1R* variants (Supplementary Table 5a and 5b) or skin cancer risk factors including constitutional susceptibility score (tertiles), family history of skin cancer, the number of lifetime severe sunburns that blistered, sunlamp use or tanning salon attendance, cumulative sun exposure while wearing a bathing suit, and geographic regions (either by 11 states or 3 combined groups) (data not shown). None of those significant associations with skin cancer risk remained significant after the Bonferroni correction (all *p*-values >0.05/45 (15 SNPs and 3 types of skin cancer) =0.001).

Haplotypes for the TYR, OCA2, SLC45A2, and ASIP genes and skin cancer risk

We performed the global test to evaluate the difference in haplotype frequencies between cases and controls (Table 5). We found significant differences in *TYR* haplotype frequency for SCC (*p*-value =0.007), *OCA2* haplotype frequency for BCC (*p*-value =0.03), and *ASIP* haplotype frequencies for melanoma and SCC (*p*-value =0.008 and 0.004, respectively). For the *TYR* gene, the haplotypes that carried only one variant allele at the two sites were significantly associated with an increased risk of SCC. The adjusted ORs (95% CI) for the haplotype carrying only the Ser192Tyr or only the Arg402Gln variant alleles were 1.48 (1.16–1.89) and 1.35 (1.04–1.74), respectively. The Arg402Gln variant was not significantly associated with risk of SCC in the single SNP analysis. We observed that the haplotype carrying *OCA2* Arg419Gln variant allele and the *OCA2* Arg305Trp major allele was significantly associated with an increased risk of BCC (adjusted OR, 1.62; 95% CI, 1.13–2.32). For the *ASIP* gene, the haplotype AH was significantly associated with an increased risk of melanoma (OR, 1.68; 95% CI, 1.18–2.39) and SCC (OR, 1.54; 95% CI, 1.08–2.19). The *ASIP* rs4911414 variant allele was not significantly associated with melanoma risk in the single SNP analysis.

Power calculation

The Quanto statistical software version 1.2.3 was used for power calculation ³⁶. We calculated the power to detect the specified ORs at various allele frequencies of variant allele in additive models. The calculations were based on a two-sided alpha of 0.05, and the particular sizes of different phenotypic population groups presented in the Table 1 of this study. For melanoma (SCC or BCC), we have 80% power to detect an OR of 1.80 (1.72 or 1.70), 1.48 (1.42 or 1.41), and 1.35 (1.32 or 1.31) if the minor allele frequency is 5%, 15%, and 40%, respectively. For pigmentary phenotypes, we calculated the power to detect the difference between dark and light pigmentation: black/brown and blonde hair color, medium/olive and fair skin color, and average/deep tan and practically none/light tan. For hair color (skin color or tanning ability), we have 80% power to detect an OR of 2.26 (1.99 or 1.90), 1.71 (1.52 or 1.50), and 1.52 (1.36 or 1.35) if the minor allele frequency is 5%, 15%, and 40%, respectively.

Discussion

Hair color and skin color show striking variations between human subgroups. The dark pigmentation and tanning response protect the skin from UV 37 . To date, although more than 100 candidate pigmentation genes containing common genetic variants have been identified, only the variants in the *MC1R* gene have been consistently implicated in the variation of pigmentary phenotypes as well as skin cancer risk 5 , 29 , 34 , $^{38-40}$. In our study only the three *MC1R* RHC variants were significantly associated with red hair color, supporting the major contribution of the *MC1R* gene to the red hair color phenotype, an autosomal recessive trait 28 , 29 , 33 , 41 . In addition, some genetic variants in the other pigmentation genes showed

significant associations with non-red hair color (black to blonde) in this study, suggesting distinct mechanisms in the formation of non-red hair color and red hair color. Previous studies reported possible associations between some genetic variants evaluated in this study and pigmentary phenotypes. We summarized these studies in Supplementary Table 6.

TYR Arg402Gln, a common polymorphism of tyrosinase, was correlated with reduced pigmentation of the retina and iris resulting from low tyrosinase activity ⁴². In addition to the associations of this SNP with skin color and tanning ability observed in this study, Sulem et al. reported that this SNP was associated with eye color and possibly with blond hair color ²⁸. Mutations in murine *SLC45A2* gene lead to hypopigmentation of the eyes and fur ⁴³. Two non-synonymous SNPs in this gene, *SLC45A2* Phe374Leu and *SLC45A2* Glu272Lys, were associated with darker pigmentary phenotypes in our study, which is consistent with a previous report ⁴⁴. However, our multivariate analysis mutually adjusting for these two SNPs showed that the effect of *SLC45A2* Glu272Lys on pigmentary phenotypes was explained by the variant *SLC45A2* Phe374Leu. For the promoter polymorphism *SLC45A2* -1721 C>G, we did not detect any significant associations with pigmentary traits, while a previous study reported an association between this SNP and olive skin color ⁴⁵.

The deletion of *OCA2* gene has been linked to reduced pigmentation of skin, hair, and eyes in Prader-Willi Syndrome ⁴⁶. Two genetic variants in this gene, Arg305Trp and Arg419Gln, have been correlated with dark eye color ⁴⁷. However, these two SNPs were not associated with pigmentary phenotypes measured in our study, such as hair color, skin color, and tanning ability except that the Arg305Trp was marginally associated with skin color. A polymorphism in the 3' untranslated region of *ASIP* gene (g.8818 A>G) has been previously reported to be associated with dark pigmentary phenotypes among populations of African Americans or European-ancestry ^{48–51}. Although we did not find a significant association of this SNP with any of the pigmentary phenotypes, our haplotype analysis showed that the haplotype *ASIP* AH was significantly associated with fair skin color and this association remained significant after adjusting for *ASIP* g.8818 A>G. Similarly, Sulem et al. reported that the *ASIP* AH haplotype remained significant for the pigmentary traits, such as burning and freckling, after adjusting for *ASIP* g.8818 A>G, while the association of *ASIP* g.8818 A>G with pigmentary traits were eliminated after adjusting for the haplotype ²⁷.

We evaluated the contributions of genetic variants in the pigmentation genes not only to pigmentary phenotypes but also to the risks of three types of skin cancers among U.S. Caucasians, whereas most previous studies only evaluated the relation of those genetic variants to the pigmentary traits. Ours is the first report evaluating the association between genetic variants in the pigmentation genes and the three types of skin cancer simultaneously. We summarized the results from previous studies assessing the associations of the SNPs evaluated in this study with melanoma risk in Supplementary Table 7. Only one previous study examined pigmentation genes with BCC risk ²⁵. Overall, in this study, the associations observed with an altered risk of at least one skin cancer in the single SNP analysis remained similar after adjusting for either pigmentary phenotypes or MC1R variants, suggesting that these genetic variants play a role in development of skin cancer beyond their influence on pigmentary phenotypes. Furthermore, most of these genetic variants were not associated with the pigmentary phenotypes. The genes involved in pigmentation process may also contribute to other cellular responses to UV exposure. For example, the immune and inflammatory responses to UV exposure are at least partially mediated by the *MC1R* gene 52-54. Also, the *OCA2* gene increases cellular sensitivity to toxic compounds in addition to its role in controlling melanosome biogenesis ⁵⁵. In addition, tyrosinase is recognized as melanoma-associated antigen by cytotoxic T lymphocytes 56. It is therefore plausible that these genetic variants associated with skin cancer risks may influence other cellular responses leading to skin cancer development. However, we cannot rule out the possibility that the associations with skin cancer

risk could be due to chance considering the number of tests performed. Therefore, we should be cautious when interpreting the results on skin cancer risks.

Recently, Gudbjartsson et al. reported a significant association of the *TYR* 402Gln variant and the *ASIP* AH haplotype with the increased risks of melanoma and BCC ²⁵. The haplotype analysis performed in our study showed that the risk estimate associated with the *TYR* 402Gln was elevated for melanoma (OR, 1.29; 95% CI, 0.97–1.71) and SCC (OR, 1.35; 95% CI, 1.04–1.74), which was not observed in the single SNP analysis. For the *ASIP* AH haplotype, in addition to the association with an increased risk of melanoma, we also found significant association with an increased risk of SCC. The inverse association between the *OCA2* Arg305Trp polymorphism and melanoma risk among French Caucasians reported by Jannot et al. is inconsistent with the result of our study ⁵⁷. We did not find any significant associations between this SNP and three types of skin cancer risks in this study.

Two of the four regions that we found to be associated with variation in pigmentary phenotypes among Europeans (*SLC45A2* and *OCA2*) show strong evidence of recent positive selection, based on a comparison of allele frequencies across samples from three continental populations (Africa, Asia, and Europe) ⁵⁸. Allele frequencies for the *SLC45A2* Phe374Leu polymorphism have been shown to vary greatly across continental populations ⁵⁸, and less drastically within Europe ⁵⁹. The *TYR* SNP rs1126809 Arg402Gln also shows significant differences in allele frequency across the HapMap CEU, CHB, JPT, and YRI panels. This SNP and its surrogate SNP rs1393350 were monomorphic in CHB, JPT, and YRI panels (the minor allele was absent from these samples).

Eight SNPs out of the 15 SNPs were either genotyped as part of the Cancer Genetic Markers of Susceptibility (CGEMS) breast cancer genome-wide association scan or could be imputed with high confidence using the observed genotypes and the HapMap phased data 60 . The CGEMS breast cancer scan consists of 1200 cases of breast cancer and 1200 controls from the Nurses' Health Study of European ancestry genotyped using the Illumina 500k HumanHap platform ⁶¹. In order to assess the potential for within-Europe population stratification bias, we examined the association between these 8 SNPs and the top principal components of genetic variation inferred from the CGEMS genome-wide scan data 62, 63. For example, the *TYR* rs1393350 SNP, which was strongly associated with skin color and tanning ability in the skin cancer controls, was also significantly associated with two of the top 10 principal components of genetic variation (Supplementary Table 8), suggesting that allele frequency for this marker also vary among European populations. This SNP was strongly associated with tanning ability (information on the skin color is not recorded in the CGEMS data) in the CGEMS genomewide association study samples (*p*-value $=5.8 \times 10^{-11}$), and this association remained significant after adjusting for the top four principal components (*p*-value = 8.0×10^{-8}). In fact, only 3 of the top ten principal components were associated with tanning ability, and together these explained 4.5% of the residual variation in tanning ability, while the TYR rs1126809 (a surrogate for Arg402Gln) polymorphism explained 1.5% of the residual variation in tanning ability beyond the effect of top 3 principal components. We believe it is unlikely that the strong associations we see between these markers and pigmentary phenotypes are solely due to population stratification bias. Rather it is likely that differences in the distribution of pigmentary phenotypes across Europe are due in part to differences in allele frequencies at these loci and other as-yet-unknown loci.

Population stratification may be a particularly important issue in assessment of the association of the pigmentation genetic polymorphism with skin cancer risk because of the variation of the allele frequency and the predominance of the disease among light pigmented people, even among European populations. However, the ancestry informative variants mentioned above were not associated with any type of skin cancer, suggesting that the associations of other

variants with skin cancer risk is not due to bias rooted in stratification, a possibility that is also made less likely by the fact that these associations remained significant after controlling for the geographic regions (either by 11 states or 3 combined groups). However, these modest associations require further replication in other populations.

One limitation of this study would be the modest statistical power. It is possible that the modest effects of some genetic variants cannot be detected due to insufficient statistical power. Another limitation of our study was that we used self-reported pigmentary phenotypes. Such assessment may miss certain aspects of pigmentary phenotypes influenced by these genetic variants, such as melanin content and composition 64 , 65 . In addition, misclassification is always a concern in epidemiologic studies. The high education level and interest in health of cohort members allows high quality information to be collected. Test-retest reliability of collecting phenotypic factors from questionnaires is moderate to substantial, including skin color, tanning/burning tendency, and sunburn history $^{66-68}$.

In conclusion, our study evaluated the associations between genetic variants in the pigmentation genes and pigmentary phenotypes and skin cancer risk. As this reported is one of the very few studies examining such associations, additional studies are warranted to confirm these associations. This information may be useful in understanding the involvement of different pigmentation genes in Caucasian pigmentary phenotypes and skin cancer risk.

Acknowledgments

We thank Dr. Hardeep Ranu and Ms. Pati Soule for their laboratory assistance, and Ms. Carolyn Guo and Ms. Constance Chen for their programming support. We are indebted to the participants in the Nurses' Health Study for their dedication and commitment.

Grant sponsor: NIH; Grant numbers: CA128080 and CA132175.

Abbreviations

BCC	basal cell carcinoma
SCC	squamous cell carcinoma
CI	confidence interval
OR	odds ratio
UV	ultraviolet

References

- Frisancho AR, Wainwright R, Way A. Heritability and components of phenotypic expression in skin reflectance of Mestizos from the Peruvian lowlands. Am J Phys Anthropol 1981;55:203–8. [PubMed: 7258341]
- Harrison GA, Owen JJ. Studies on the Inheritance of Human Skin Colour. Ann Hum Genet 1964;28:27– 37. [PubMed: 14204850]
- 3. Jablonski NG, Chaplin G. The evolution of human skin coloration. J Hum Evol 2000;39:57–106. [PubMed: 10896812]

- Nordlund, JJ.; Boissy, RE.; Hearing, VJ.; King, RA.; Ortonne, JP. The pigmentary system Physiology and pathophysiology. Oxford University Press; Oxford: 1998.
- Jackson IJ. Molecular and developmental genetics of mouse coat color. Annu Rev Genet 1994;28:189– 217. [PubMed: 7893123]
- Schauer E, Trautinger F, Kock A, Schwarz A, Bhardwaj R, Simon M, Ansel JC, Schwarz T, Luger TA. Proopiomelanocortin-derived peptides are synthesized and released by human keratinocytes. J Clin Invest 1994;93:2258–62. [PubMed: 8182158]
- Barsh G, Gunn T, He L, Schlossman S, Duke-Cohan J. Biochemical and genetic studies of pigmenttype switching. Pigment Cell Res 2000;13(Suppl 8):48–53. [PubMed: 11041357]
- D'Orazio JA, Nobuhisa T, Cui R, Arya M, Spry M, Wakamatsu K, Igras V, Kunisada T, Granter SR, Nishimura EK, Ito S, Fisher DE. Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning. Nature 2006;443:340–4. [PubMed: 16988713]
- Furumura M, Sakai C, Abdel-Malek Z, Barsh GS, Hearing VJ. The interaction of agouti signal protein and melanocyte stimulating hormone to regulate melanin formation in mammals. Pigment Cell Res 1996;9:191–203. [PubMed: 8948501]
- Wilson BD, Ollmann MM, Kang L, Stoffel M, Bell GI, Barsh GS. Structure and function of ASP, the human homolog of the mouse agouti gene. Hum Mol Genet 1995;4:223–30. [PubMed: 7757071]
- Gunn TM, Miller KA, He L, Hyman RW, Davis RW, Azarani A, Schlossman SF, Duke-Cohan JS, Barsh GS. The mouse mahogany locus encodes a transmembrane form of human attractin. Nature 1999;398:152–6. [PubMed: 10086356]
- He L, Gunn TM, Bouley DM, Lu XY, Watson SJ, Schlossman SF, Duke-Cohan JS, Barsh GS. A biochemical function for attractin in agouti-induced pigmentation and obesity. Nat Genet 2001;27:40–7. [PubMed: 11137996]
- Sturm RA, O'Sullivan BJ, Box NF, Smith AG, Smit SE, Puttick ER, Parsons PG, Dunn IS. Chromosomal structure of the human TYRP1 and TYRP2 loci and comparison of the tyrosinaserelated protein gene family. Genomics 1995;29:24–34. [PubMed: 8530077]
- Sturm RA, Teasdale RD, Box NF. Human pigmentation genes: identification, structure and consequences of polymorphic variation. Gene 2001;277:49–62. [PubMed: 11602344]
- 15. Jimbow K, Hua C, Gomez PF, Hirosaki K, Shinoda K, Salopek TG, Matsusaka H, Jin HY, Yamashita T. Intracellular vesicular trafficking of tyrosinase gene family protein in eu- and pheomelanosome biogenesis. Pigment Cell Res 2000;13(Suppl 8):110–7. [PubMed: 11041367]
- Spritz RA. Molecular genetics of oculocutaneous albinism. Hum Mol Genet 1994;3:1469–75. [PubMed: 7849740]Spec No
- Fuller BB, Spaulding DT, Smith DR. Regulation of the catalytic activity of preexisting tyrosinase in black and Caucasian human melanocyte cell cultures. Exp Cell Res 2001;262:197–208. [PubMed: 11139343]
- Puri N, Gardner JM, Brilliant MH. Aberrant pH of melanosomes in pink-eyed dilution (p) mutant melanocytes. J Invest Dermatol 2000;115:607–13. [PubMed: 10998131]
- Rinchik EM, Bultman SJ, Horsthemke B, Lee ST, Strunk KM, Spritz RA, Avidano KM, Jong MT, Nicholls RD. A gene for the mouse pink-eyed dilution locus and for human type II oculocutaneous albinism. Nature 1993;361:72–6. [PubMed: 8421497]
- Smith DR, Spaulding DT, Glenn HM, Fuller BB. The relationship between Na(+)/H(+) exchanger expression and tyrosinase activity in human melanocytes. Exp Cell Res 2004;298:521–34. [PubMed: 15265699]
- 21. Lamason RL, Mohideen MA, Mest JR, Wong AC, Norton HL, Aros MC, Jurynec MJ, Mao X, Humphreville VR, Humbert JE, Sinha S, Moore JL, et al. SLC24A5, a putative cation exchanger, affects pigmentation in zebrafish and humans. Science 2005;310:1782–6. [PubMed: 16357253]
- 22. Schnetkamp PP. The SLC24 Na+/Ca2+-K+ exchanger family: vision and beyond. Pflugers Arch 2004;447:683–8. [PubMed: 14770312]
- 23. Han J, Colditz GA, Hunter DJ. Risk factors for skin cancers: a nested case-control study within the Nurses' Health Study. Int J Epidemiol 2006;35:1514–21. [PubMed: 16943234]
- 24. Brown KM, Macgregor S, Montgomery GW, Craig DW, Zhao ZZ, Iyadurai K, Henders AK, Homer N, Campbell MJ, Stark M, Thomas S, Schmid H, et al. Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet 2008;40:838–40. [PubMed: 18488026]

- 25. Gudbjartsson DF, Sulem P, Stacey SN, Goldstein AM, Rafnar T, Sigurgeirsson B, Benediktsdottir KR, Thorisdottir K, Ragnarsson R, Sveinsdottir SG, Magnusson V, Lindblom A, et al. ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat Genet 2008;40:886–91. [PubMed: 18488027]
- 26. Han J, Kraft P, Nan H, Guo Q, Chen C, Qureshi A, Hankinson SE, Hu FB, Duffy DL, Zhao ZZ, Martin NG, Montgomery GW, et al. A genome-wide association study identifies novel alleles associated with hair color and skin pigmentation. PLoS Genet 2008;4:e1000074. [PubMed: 18483556]
- Sulem P, Gudbjartsson DF, Stacey SN, Helgason A, Rafnar T, Jakobsdottir M, Steinberg S, Gudjonsson SA, Palsson A, Thorleifsson G, Palsson S, Sigurgeirsson B, et al. Two newly identified genetic determinants of pigmentation in Europeans. Nat Genet 2008;40:835–7. [PubMed: 18488028]
- Sulem P, Gudbjartsson DF, Stacey SN, Helgason A, Rafnar T, Magnusson KP, Manolescu A, Karason A, Palsson A, Thorleifsson G, Jakobsdottir M, Steinberg S, et al. Genetic determinants of hair, eye and skin pigmentation in Europeans. Nat Genet 2007;39:1443–52. [PubMed: 17952075]
- 29. Han J, Kraft P, Colditz GA, Wong J, Hunter DJ. Melanocortin 1 receptor variants and skin cancer risk. Int J Cancer 2006;119:1976–84. [PubMed: 16721784]
- Colditz GA, Martin P, Stampfer MJ, Willett WC, Sampson L, Rosner B, Hennekens CH, Speizer FE. Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. Am J Epidemiol 1986;123:894–900. [PubMed: 3962971]
- Hunter DJ, Colditz GA, Stampfer MJ, Rosner B, Willett WC, Speizer FE. Risk factors for basal cell carcinoma in a prospective cohort of women. Ann Epidemiol 1990;1:13–23. [PubMed: 1669486]
- Flanagan N, Healy E, Ray A, Philips S, Todd C, Jackson IJ, Birch-Machin MA, Rees JL. Pleiotropic effects of the melanocortin 1 receptor (MC1R) gene on human pigmentation. Hum Mol Genet 2000;9:2531–7. [PubMed: 11030758]
- Healy E, Jordan SA, Budd PS, Suffolk R, Rees JL, Jackson IJ. Functional variation of MC1R alleles from red-haired individuals. Hum Mol Genet 2001;10:2397–402. [PubMed: 11689486]
- 34. Rees JL. Genetics of hair and skin color. Annu Rev Genet 2003;37:67-90. [PubMed: 14616056]
- Kraft P, Cox DG, Paynter RA, Hunter D, De Vivo I. Accounting for haplotype uncertainty in matched association studies: a comparison of simple and flexible techniques. Genet Epidemiol 2005;28:261– 72. [PubMed: 15637718]
- 36. Gauderman, WJ.; Morrison, JM. QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies. 2006. http://hydra.usc.edu/gxe
- Lin JY, Fisher DE. Melanocyte biology and skin pigmentation. Nature 2007;445:843–50. [PubMed: 17314970]
- 38. Bastiaens MT, ter Huurne JA, Kielich C, Gruis NA, Westendorp RG, Vermeer BJ, Bavinck JN. Melanocortin-1 receptor gene variants determine the risk of nonmelanoma skin cancer independently of fair skin and red hair. Am J Hum Genet 2001;68:884–94. [PubMed: 11254446]
- 39. Kennedy C, ter Huurne J, Berkhout M, Gruis N, Bastiaens M, Bergman W, Willemze R, Bavinck JN. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 2001;117:294– 300. [PubMed: 11511307]
- 40. Palmer JS, Duffy DL, Box NF, Aitken JF, O'Gorman LE, Green AC, Hayward NK, Martin NG, Sturm RA. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet 2000;66:176–86. [PubMed: 10631149]
- Valverde P, Healy E, Jackson I, Rees JL, Thody AJ. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995;11:328–30. [PubMed: 7581459]
- 42. Fukai K, Holmes SA, Lucchese NJ, Siu VM, Weleber RG, Schnur RE, Spritz RA. Autosomal recessive ocular albinism associated with a functionally significant tyrosinase gene polymorphism. Nat Genet 1995;9:92–5. [PubMed: 7704033]
- Sweet HO, Brilliant MH, Cook SA, Johnson KR, Davisson MT. A new allelic series for the underwhite gene on mouse chromosome 15. J Hered 1998;89:546–51. [PubMed: 9864865]

- 44. Graf J, Hodgson R, van Daal A. Single nucleotide polymorphisms in the MATP gene are associated with normal human pigmentation variation. Hum Mutat 2005;25:278–84. [PubMed: 15714523]
- 45. Graf J, Voisey J, Hughes I, van Daal A. Promoter polymorphisms in the MATP (SLC45A2) gene are associated with normal human skin color variation. Hum Mutat 2007;28:710–7. [PubMed: 17358008]
- 46. Spritz RA, Bailin T, Nicholls RD, Lee ST, Park SK, Mascari MJ, Butler MG. Hypopigmentation in the Prader-Willi syndrome correlates with P gene deletion but not with haplotype of the hemizygous P allele. Am J Med Genet 1997;71:57–62. [PubMed: 9215770]
- Rebbeck TR, Kanetsky PA, Walker AH, Holmes R, Halpern AC, Schuchter LM, Elder DE, Guerry D. P gene as an inherited biomarker of human eye color. Cancer Epidemiol Biomarkers Prev 2002;11:782–4. [PubMed: 12163334]
- Bonilla C, Boxill LA, Donald SA, Williams T, Sylvester N, Parra EJ, Dios S, Norton HL, Shriver MD, Kittles RA. The 8818G allele of the agouti signaling protein (ASIP) gene is ancestral and is associated with darker skin color in African Americans. Hum Genet 2005;116:402–6. [PubMed: 15726415]
- Kanetsky PA, Swoyer J, Panossian S, Holmes R, Guerry D, Rebbeck TR. A polymorphism in the agouti signaling protein gene is associated with human pigmentation. Am J Hum Genet 2002;70:770– 5. [PubMed: 11833005]
- 50. Meziani R, Descamps V, Gerard B, Matichard E, Bertrand G, Archimbaud A, Ollivaud L, Saiag P, Lebbe C, Basset-Seguin N, Alberti C, Crickx B, et al. Association study of the g.8818A>G polymorphism of the human agouti gene with melanoma risk and pigmentary characteristics in a French population. J Dermatol Sci 2005;40:133–6. [PubMed: 16183259]
- Voisey J, Gomez-Cabrera Mdel C, Smit DJ, Leonard JH, Sturm RA, van Daal A. A polymorphism in the agouti signalling protein (ASIP) is associated with decreased levels of mRNA. Pigment Cell Res 2006;19:226–31. [PubMed: 16704456]
- Kalden DH, Scholzen T, Brzoska T, Luger TA. Mechanisms of the antiinflammatory effects of alpha-MSH. Role of transcription factor NF-kappa B and adhesion molecule expression. Ann N Y Acad Sci 1999;885:254–61. [PubMed: 10816658]
- 53. Luger TA, Scholzen TE, Brzoska T, Bohm M. New insights into the functions of alpha-MSH and related peptides in the immune system. Ann N Y Acad Sci 2003;994:133–40. [PubMed: 12851308]
- 54. Roberts DW, Newton RA, Beaumont KA, Helen Leonard J, Sturm RA. Quantitative analysis of MC1R gene expression in human skin cell cultures. Pigment Cell Res 2006;19:76–89. [PubMed: 16420249]
- 55. Staleva L, Manga P, Orlow SJ. Pink-eyed dilution protein modulates arsenic sensitivity and intracellular glutathione metabolism. Mol Biol Cell 2002;13:4206–20. [PubMed: 12475946]
- Kirkin AF, Dzhandzhugazyan K, Zeuthen J. The immunogenic properties of melanoma-associated antigens recognized by cytotoxic T lymphocytes. Exp Clin Immunogenet 1998;15:19–32. [PubMed: 9619397]
- 57. Jannot AS, Meziani R, Bertrand G, Gerard B, Descamps V, Archimbaud A, Picard C, Ollivaud L, Basset-Seguin N, Kerob D, Lanternier G, Lebbe C, et al. Allele variations in the OCA2 gene (pink-eyed-dilution locus) are associated with genetic susceptibility to melanoma. Eur J Hum Genet 2005;13:913–20. [PubMed: 15889046]
- 58. Barreiro LB, Laval G, Quach H, Patin E, Quintana-Murci L. Natural selection has driven population differentiation in modern humans. Nat Genet 2008;40:340–5. [PubMed: 18246066]
- Yuasa I, Umetsu K, Harihara S, Kido A, Miyoshi A, Saitou N, Dashnyam B, Jin F, Lucotte G, Chattopadhyay PK, Henke L, Henke J. Distribution of the F374 allele of the SLC45A2 (MATP) gene and founder-haplotype analysis. Ann Hum Genet 2006;70:802–11. [PubMed: 17044855]
- Browning SR, Browning BL. Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering. Am J Hum Genet 2007;81:1084–97. [PubMed: 17924348]
- Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, Wang J, Yu K, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007;39:870–4. [PubMed: 17529973]
- 62. Reich D, Price AL, Patterson N. Principal component analysis of genetic data. Nat Genet 2008;40:491–2. [PubMed: 18443580]

- Yu K, Wang Z, Li Q, Wacholder S, Hunter DJ, Hoover RN, Chanock S, Thomas G. Population substructure and control selection in genome-wide association studies. PLoS ONE 2008;3:e2551. [PubMed: 18596976]
- 64. Alaluf S, Heath A, Carter N, Atkins D, Mahalingam H, Barrett K, Kolb R, Smit N. Variation in melanin content and composition in type V and VI photoexposed and photoprotected human skin: the dominant role of DHI. Pigment Cell Res 2001;14:337–47. [PubMed: 11601655]
- 65. Rees JL. The genetics of sun sensitivity in humans. Am J Hum Genet 2004;75:739–51. [PubMed: 15372380]
- 66. Branstrom R, Kristjansson S, Ullen H, Brandberg Y. Stability of questionnaire items measuring behaviours, attitudes and stages of change related to sun exposure. Melanoma Res 2002;12:513–9. [PubMed: 12394194]
- 67. Glanz K, Schoenfeld E, Weinstock MA, Layi G, Kidd J, Shigaki DM. Development and reliability of a brief skin cancer risk assessment tool. Cancer Detect Prev 2003;27:311–5. [PubMed: 12893080]
- Westerdahl J, Anderson H, Olsson H, Ingvar C. Reproducibility of a self-administered questionnaire for assessment of melanoma risk. Int J Epidemiol 1996;25:245–51. [PubMed: 9119548]



Figure 1. The function of select pigmentation genes in the pigmentation pathway

Induction of POMC/ α -MSH activates the *MC1R*, inducing cAMP production in melanocyte. This elevated signaling leads to eumelanin production, resulting in the maturation of the pheomelanosome to the eumelanosome. Attractin (*ATRN*) is a low-affinity receptor for agouti signaling protein (*ASIP*), an antagonist of *MC1R*. Some proteins, such as TYR, TYRP1, P-protein, SLC24A5, and MATP, are involved in inducing melanization of pheomelanosome or eumelanosome, as described in the text.

 Table 1

 Characteristics of skin cancer cases and controls in the nested case-control study
 NIH-PA Author Manuscript

NIH-PA Author Manuscript

_
~
_
_
_
_
U
-
-
_
_
_
\sim
0
_
_
2
\leq
Ň
Ma
Mai
Mar
Man
Manu
Manu
Manus
Manus
Manus
Manusc
Manusci
Manuscri
Manuscri
Manuscrip
Manuscrip:
Manuscript

Nan	et	al.

Characteristic	Controls (n=870)	Melanoma cases (n=218)	SCC cases (n=285)	BCC cases (n=300)
Age at diagnosis (mean, years)	64.5	63.4	64.7	64.0
Natural hair color at age 20 (%)				
Black or dark brown	43.9	31.5	41.3	30.3
Light brown	40.0	42.5	34.6	45.7
Blonde	12.0	15.5	16.8	18.0
Red	2.9	10.5	5.2	4.7
Natural skin color (%)				
Fair	40.0	57.1	54.6	53.0
Medium	36.7	25.6	32.2	31.3
Olive	4.8	0.9	1.8	1.3
Tanning ability (%)				
Practically none	8.3	13.8	13.9	11.7
Light tan	21.1	29.5	24.1	25.5
Average tan	47.3	40.0	47.4	46.5
Tan	23.3	16.7	14.7	16.3
Geographic region at baseline (%)				
Northeast	55.2	58.0	51.7	49.3
Northcentral	23.4	16.9	17.1	20.3
West and South	21.4	25.1	31.1	30.3
Family history of skin cancer (%)	25.1	36.5	35.7	42.7
Sunlamp use or tanning salon attendance (%)	10.0	19.2	14.3	14.7
Highest tertile of cumulative sun exposure with a bathing suit (%)	33.4	53.3	46.1	42.6
Number of lifetime severe sunburns (mean)	5.4	9.6	7.8	8.2

Page 15

The percentages may not sum to 100 due to rounding.

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Table 2

Fifteen SNPs in the selected pigmentation genes

SNP	#SI	Gene	Protein	MAF - controls (%)	MAF - CEU (%) ^c	MAF - CHB/JPT (%) ^d	MAF - YRI (%) ^e
TYR Ser192Tyr	rs1042602	TYR	Tyrosinase	35	42	0	0
TYR Arg402Gln	rs1126809 ^a	TYR	Tyrosinase	ı	22	0	0
<i>TYR</i> -6895 G>A	rs1393350 ^a	TYR	Tyrosinase	28	19	0	0
TYRP1 C>T	rs1408799	TYRP1	Tyrosinase-related protein 1	32	30	98	78
OCA2 Arg305Trp	rs1800401	OCA2	P-protein	9	,		
OCA2 Arg419Gln	rs1800407	OCA2	P-protein	9	7	0	0
<i>SLC45A2</i> -1721 C>G	rs13289	SLC45A2	MATP	40	32	34	73
SLC45A2 Glu272Lys	rs26722	SLC45A2	MATP	2	0	40	5
SLC45A2 Phe374Leu	rs16891982	SLC45A2	MATP	4	2	66	100
SLC24A5 intron2 T>C	rs17426596	SLC24A5	SLC24A5	4	ε	0	0
POMC3' UTR C>T	rs1042571	POMC	POMC, MSH, ACTH	19	ı	ı	·
ASIPG>T	rs4911414	ASIP	Agouti signaling protein	31	28	19	13
ASIPG>A	rs1015362	ASIP	Agouti signaling protein	27	23	19	83
<i>ASIP</i> g.8818 A>G	rs6058017	ASIP	Agouti signaling protein	13	I	ı	ı
ATRN Ile426Thr	rs17782078	ATRN	Attractin	5	4	0	0
ATRN Arg1152Lys	rs3886999	ATRN	Attractin	9	4	0	0

 a The SNP rs1126809 failed the assay and the rs1393350 was genotyped instead (D'=1 and r2=0.86).

 \boldsymbol{b} Minor allele frequency (MAF) was calculated among controls in this study.

^cMAF was based on the HapMap CEU (Utah residents with ancestry from northern and western Europe) samples.

^dMAF was based on the HapMap CHB and JPT (CHB: Han Chinese in Beijing, China; JPT: Japanese in Tokyo, Japan) samples.

 $^{e}\!\mathrm{MAF}$ was based on the HapMap YRI (Yoruba in Ibadan, Nigeria) samples.

_
_
_
_
_
~
-
-
12
-
_
_
-
()
<u> </u>
_
_
~
~
_
01
U)
_
_
_
-
<u> </u>
(n)
.
0
_
()
<u> </u>

NIH-PA Author Manuscript

Nan et al.

SNP	Hair co	olor (black to	blonde)	Hair co	olor (red vs.	nonred)		Skin color		E	anning abili	ity
	ß	SE	<i>p</i> -value	β	SE	<i>p</i> -value	ß	SE	<i>p</i> -value	В	SE	<i>p</i> -value
TYR Ser192Tyr	0.08	0.04	0.06	-0.26	0.33	0.42	0.06	0.04	0.10	0.00	0.05	0.97
<i>TYR</i> Arg402Gln ^{**}	0.00	0.04	0.92	-0.31	0.35	0.38	-0.12	0.04	7.7E-04	-0.16	0.05	7.3E-04
<i>TYRP1</i> C>T (rs1408799)	0.02	0.04	0.60	0.32	0.30	0.28	0.02	0.04	0.65	0.04	0.05	0.46
OCA2 Arg305Trp	-0.08	0.08	0.31	0.11	0.62	0.85	0.15	0.07	0.04	0.02	0.10	0.84
OCA2 Arg419Gln	-0.09	0.08	0.23	-1.05	1.01	0.30	-0.10	0.07	0.18	-0.05	0.09	0.61
<i>SLC45A2</i> -1721 C>G	0.03	0.04	0.49	-0.11	0.30	0.71	0.02	0.03	0.64	0.04	0.04	0.33
SLC45A2 Glu272Lys	-0.58	0.14	6.0E-05		·	1.00^*	0.44	0.13	1.1E-03	0.48	0.18	7.0E-03
SLC45A2 Phe374Leu	-0.49	0.10	2.4E-07	0.51	09.0	0.39	0.48	0.09	1.1E-07	0.42	0.11	2.5E-04
SLC24A5 intron2 T>C	0.11	0.10	0.26	0.97	0.54	0.08	-0.08	0.08	0.34	-0.03	0.12	0.78
POMC 3' UTR C>T	-0.06	0.05	0.23	0.09	0.36	0.79	-0.03	0.04	0.52	-0.01	0.06	0.86
ASIP G>T (rs4911414)	0.02	0.04	0.68	0.33	0.30	0.27	-0.11	0.03	1.4E-03	-0.11	0.05	0.02
ASIP G>A (rs1015362)	-0.06	0.04	0.15	-0.37	0.35	0.29	-0.01	0.04	0.76	0.00	0.05	0.96
<i>ASIP</i> g.8818 A>G	-0.01	0.06	0.81	0.07	0.44	0.88	0.00	0.05	0.98	0.08	0.07	0.25
ATRN Ile426Thr	0.04	0.08	0.65	0.50	0.54	0.35	-0.07	0.07	0.31	-0.02	0.10	0.87
ATRN Arg1152Lys	0.05	0.08	0.50	0.45	0.53	0.40	-0.08	0.07	0.24	-0.02	0.10	0.82
<i>MCIR</i> variants												
MCIR Val60Leu	-0.03	0.05	0.63	-1.91	1.01	0.06	-0.06	0.05	0.23	-0.13	0.06	0.05
MCIR Val92Met	-0.13	0.06	0.04	ı	ī	0.01^*	0.00	0.06	1.00	-0.10	0.07	0.18
MCIR Arg151Cys	0.17	0.08	0.03	2.21	0.40	2.6E-08	-0.24	0.06	1.4E-04	-0.46	0.09	1.4E-07
MCIR lle155Thr	0.09	0.16	0.58	ı	ï	1.00^*	-0.05	0.13	0.71	-0.18	0.19	0.34
MCIR Arg160Trp	0.20	0.07	5.9E-03	2.14	0.34	5.0E-10	-0.19	0.06	9.4E-04	-0.28	0.08	4.1E-04
MCIR Arg163Gln	0.05	0.09	0.58	ı	ı	0.25^*	0.01	0.09	0.92	-0.07	0.11	0.54
MCIR Asp294His	0.27	0.16	0.08	1.94	0.59	9.6E-04	-0.37	0.13	4.2E-03	-0.67	0.18	2.1E-04
The regression parameter beta r SNP minor allele.	efers to the m	lean change i	n scoring in hair	color (black to	o blonde), sk	in color, and tan	ning ability (c	or change in l	og odds of red h	air for red hair	analyses) pe	r copy of the

Int J Cancer. Author manuscript; available in PMC 2010 August 15.

Fisher's exact test was used. The β value was not calculated because none of the women with red hair color carried the variant allele.

NIH-PA Author Manuscript

script
7
IIH-PA
Nuthor M
anuscrip

 Table 4

 Associations between the fifteen SNPs in the selected pigmentation genes and skin cancer risk

SNP	Melanoma		SCC		BCC	
	Additive OR [*]	p for trend	Additive OR	p for trend	Additive OR [*]	p trend
TYR Ser192Tyr	1.18 (0.94–1.48)	0.15	1.23 (1.00–1.50)	0.05	1.08 (0.89–1.33)	0.43
TYR Arg402Gln **	1.05 (0.83–1.32)	0.71	1.07 (0.87–1.32)	0.52	1.04 (0.84–1.27)	0.74
<i>TYRP1</i> C>T (rs1408799)	0.77 (0.60–0.98)	0.03	0.96 (0.78–1.18)	0.71	0.95 (0.77–1.16)	0.60
OCA2 Arg305Trp	0.92 (0.56–1.52)	0.76	0.87 (0.56–1.36)	0.55	0.97 (0.63–1.50)	0.91
OCA2 Arg419Gln	1.33 (0.89–2.01)	0.17	1.39 (0.97–2.01)	0.07	1.50 (1.06–2.13)	0.02
SLC45A2-1721 C>G	0.75 (0.60–0.95)	0.01	1.08 (0.89–1.31)	0.42	0.91 (0.75–1.11)	0.36
SLC45A2 Glu272Lys	1.19 (0.53–2.67)	0.68	0.55 (0.21–1.45)	0.23	1.04 (0.49–2.17)	0.93
SLC45A2 Phe374Leu	0.66 (0.34–1.29)	0.22	0.76 (0.43–1.34)	0.34	0.61 (0.33–1.11)	0.10
SLC24A5 intron2 T>C	0.75 (0.39–1.43)	0.38	$0.86\ (0.50{-}1.48)$	0.58	0.80(0.47 - 1.38)	0.43
POMC 3' UTR C>T	0.99 (0.74–1.31)	0.92	0.95 (0.74–1.22)	0.68	0.95 (0.75–1.22)	0.71
ASIP G>T (rs4911414)	1.21 (0.96–1.51)	0.10	1.29 (1.05–1.59)	0.01	1.16 (0.95–1.42)	0.14
ASIP G>A (rs1015362)	0.89 (0.69–1.13)	0.34	1.14 (0.92–1.41)	0.23	1.06 (0.86–1.31)	0.59
<i>ASIP</i> g.8818 A>G	0.89 (0.64–1.24)	0.50	$0.79\ (0.58-1.09)$	0.15	0.73 (0.53–1.00)	0.05
ATRN Ile426Thr	0.87 (0.52–1.45)	0.59	1.14 (0.75–1.72)	0.54	1.08 (0.72–1.62)	0.72
ATRN Arg1152Lys	0.86 (0.53–1.42)	0.56	1.09 (0.72–1.63)	0.69	1.09 (0.73–1.61)	0.67
*						

Additive OR was calculated based on the unconditional logistic regression adjusted for the age.

Int J Cancer. Author manuscript; available in PMC 2010 August 15.

** TYR -6895 G>A (rs1393350) was genotyped instead.

	BCC	Cases	и %	206 37.0	1.00	190 34.2	1.05(0.83 - 1.34)	153 27.6	1.06(0.83 - 1.35)	7 1.2	0.89 (0.32–2.51)		BCC ⁶	Cases	п %	465 85.2	1.00	51 9.3	1.62 (1.13–2.32)	30 5.5	0.99 (0.64–1.53)	
kin cancer risk	scc	Cases	п %	164 31.2	1.00	206 39.4	1.48(1.16 - 1.89)	150 28.7	1.35 (1.04–1.74)	4 0.7	0.34 (0.05–2.30)		SCC	Cases	п %	468 86.7	1.00	44 8.1	1.40 (0.97–2.03)	28 5.2	0.91 (0.58–1.41)	
Table 5 <i>iLC45A2</i> , and <i>ASIP</i> genes and s	Melanoma	Cases	и %	136 32.5	1.00	157 37.6	1.34(1.03-1.75)	122 29.2	1.29 (0.97–1.71)	3 0.7	0.43 (0.07–2.79)		Melanoma	Cases	п %	351 87.3	1.00	31 7.7	1.33 (0.88–2.03)	20 5.0	0.91 (0.54–1.51)	
es for SNPs in the TYR, OCA2, S		Controls	и	618 38.0	Multivariate OR	551 33.9	Multivariate OR	438 26.9	Multivariate OR	19 1.2	Multivariate OR	A: Ser192Tyr; B: Arg402Gin ^d		Controls	п %	1417 88.3	Multivariate OR	94 5.9	Multivariate OR	93 5.8	Multivariate OR	A: Arg305Tp; B: Arg419Gln
Haplotyp	IYR		в	0		0		1		1)CA2		В	0		1		0		
			A	0		1		0		-			3		¥	0		0		1		

Int J Cancer. Author manuscript; available in PMC 2010 August 15.

Nan et al.

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

StGAX Methoda SCC Methoda Consol Co	Metanon Controls A B C n Notation 0 0 966 59,4 268 655 1 0 0 966 59,4 268 651 1 0 1 23 11,00 31,6 1 0 0 601 37,0 130 31,6 1 0 1 23 1,4 4 0,9 Rate < 1% 1 23 1,4 4 0,9 Rate < 1% 3,6 2,1,4 4 0,9 Rate < 1% 3,6 2,1,4 3,4 1,9 Ast 3,6 2,2,2 8 3,4,0,3,4,1,8,4 Ast 3,6 3,4,0,3,4,1,8,4 3,4 Ast 3,6 3,4,0,3,4,1,8,4 3,4 Ast 3,6 3,4,0,3,4,1,8,4 3,4,0,3,4,1,8,4 Ast 3,6 3,4,0,3,4,1,4,1,4,1,4,1,4,1,4,1,4,1,4,1,4,1,4	thor Manu	NIH-PA Au		nuscript	A Author Ma	NIH-P.	pt	nor Manuscri	VIH-PA Auth	7				
ABCnCase	ABCn $%$ n $%$ 00096659,4268653100000011,031,011,00100060137,011,0031,01000000,17,061,097)31,01012,31,440,0101,440,54,016,184)36,038,186)101,41,40,64,016,184)10000,04,0138,186)36,038,186)112,31,440,34,038,186)1112,30,34,016,138,186)36,038,186)1111110,34,0138,186)11 <th>SLC45A2</th> <th></th> <th></th> <th></th> <th>Melano</th> <th>ma</th> <th>Ň</th> <th>cc</th> <th>BC</th> <th>ç</th>	SLC45A2				Melano	ma	Ň	cc	BC	ç				
	A B C n $%_6$ 9.4 m $\%_6$ 0 0 0 966 59.4 268 653 1 0 0 0 37.0 130 31.6 1 0 1 23 1.4 4 0.3 1 0 1 23 1.4 4 0.3 Ruc<<1% 36 2.2 8 2.0 0.34 0.34 Ruc<1% 36 2.2 8 0.34 0.34 0.34 Ruc<1% 36 2.1/21 0.34 0.34 0.34 0.34 Ruc<1% 36 2.1/21 A 0.34 0.34 0.34 Ruc<1% 0 Multivariae OR 0.34 0.34 0.34 0.34 Ruc<1% A N N N N N N Ruc<1% N N N N N N N N<			Contr	slo [.]	Case	S	Ü	ases	Cas	ses				
		В	С	u	%	п	%	ц	%	ц	%				
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	0	0	966	59.4	268	65.5	312	57.4	357	62.1				
				Multivari	ate OR	1.00		1	.00	1.0	00				
	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	0	0	601	37.0	130	31.6	216	39.7	203	35.4				
				Multivari	ate OR	0.77 (0.61-	-0.97)	1.11 (0.	.91–1.35)	0.93 (0.7	6-1.13)				
	Rare < 1% Multivariate OR 0.54 (0.16-1.84) Rare < 1%	0	1	23	1.4	4	0.9	8	1.5	4	0.7				
Ruce (1%) 36 22 8 20 8 15 10 17 Multivariae OR 0.84(0.38-1.86) 0.66(0.29-1.50) 0.75(0.36-1.57) 0.75(0.36-1.57) 0.75(0.36-1.57) A:-1721C-G: B: Glu2721/s; C: Ple374Lat A:-1721C-G: B: Glu2721/s; C: Ple374Lat Image: State of the st	Rare < 1% 36 22 8 20 Multivariate OR 0.84 (0.38–1.86) Multivariate OR 0.84 (0.38–1.86) ASTP A: -1721C>G; B: Glu272Lys; C: Phe374Leu ASTP A ASTP Controls ASTP Controls ASTP Controls ASTP Multivariate OR 0 0 AH 1 1 1 AH 1 0 1020 65:7 253 66 10 AH 1 0 AH 1 0 AH 1 0 AH 1 6 AH 1.68 (1.18-2.39) AH 1.68 (1.18-2.39) AH 1.00 AH 1.00 AH 1.050 AH 1.00 AH 1.00 AH 1.00 AH 1.00 AH 0.09 <t< td=""><td></td><td></td><td>Multivari</td><td>ate OR</td><td>0.54 (0.16-</td><td>-1.84)</td><td>1.17 (0.</td><td>.48–2.84)</td><td>0.48 (0.1</td><td>6-1.47)</td></t<>			Multivari	ate OR	0.54 (0.16-	-1.84)	1.17 (0.	.48–2.84)	0.48 (0.1	6-1.47)				
	Multivariate OR $0.84 (0.38-1.86)$ A:-1721C>G; B: Glu272Lys; C: Phe374LeuASIP111 <t< td=""><td>e < 1%</td><td></td><td>36</td><td>2.2</td><td>8</td><td>2.0</td><td>8</td><td>1.5</td><td>10</td><td>1.7</td></t<>	e < 1%		36	2.2	8	2.0	8	1.5	10	1.7				
ASIP A:-1/21C-C; B: Glu272Lys; C: Ple374Leu ASIP Melanome ^d SCC ⁶ BCC ASIP Melanome ^d SCC ⁶ BCC ASIP Controls SCC ⁶ BCC Melanome ^d Controls SCC ⁶ BCC And D Cases Cases Cases Cases Multivariae OR D Cases Cases Cases Cases Multivariae OR D Cases Case Cases Multivariae OR D D Cases Case Case	A:-1721C>G; B: Glu272Lys; C: Phe374Leu A:-1721C>G; B: Glu272Lys; C: Phe374Leu $ASIP$ Melanoma ⁴ $ASIP$ Melanoma ⁴ $ASIP$ Controls Cases $ASIP$ Melanoma ⁴ $ASIP$ Melanoma ⁴ $ASIP$ Melanoma ⁴ $ASIP$ Melanoma ⁴ $ASIP$ Melanoma ⁶ $ASIP$ Multivariate OR 1.00 Multivariate OR 1.6 1.6 Multivariate OR 1.6 1.10 Multivariate OR 1.6 1.10 Multivariate OR 1.6 1.10 Multivariate OR 1.6 1.10 Multivariate OR 1.6 1.120 Multivariate OR 0.030 0.11 Multivariate OR 0.223 1.22 Multivariate OR <th <="" colspan="4" td=""><td></td><td></td><td>Multivari.</td><td>ate OR</td><td>0.84 (0.38-</td><td>-1.86)</td><td>0.66 (0.</td><td>.29–1.50)</td><td>0.75 (0.3</td><td>6-1.57)</td></th>	<td></td> <td></td> <td>Multivari.</td> <td>ate OR</td> <td>0.84 (0.38-</td> <td>-1.86)</td> <td>0.66 (0.</td> <td>.29–1.50)</td> <td>0.75 (0.3</td> <td>6-1.57)</td>						Multivari.	ate OR	0.84 (0.38-	-1.86)	0.66 (0.	.29–1.50)	0.75 (0.3	6-1.57)
ASIF Actional Methonal SCC ⁶ BCC BCC A B n $\sqrt{2}$ $\sqrt{2}$ $\sqrt{2}$ $\sqrt{2}$ $\sqrt{2}$ A B n $\sqrt{6}$ n $\sqrt{6}$ $\sqrt{6}$ $\sqrt{6}$ $\sqrt{6}$ 0 0 1020 65.7 253 63 294 608 $\sqrt{6}$ 1 1 1 $\sqrt{6}$ 1.00 1.00 1.00 1.00 AH 1 0 1.00 1.20 $0.90(76-1.29)$ $1.25(.99-1.58)$ 1.00 1.00 AH 1 0 1.00 1.20 $0.90(76-1.29)$ $1.25(.99-1.58)$ $1.00(.87-1.34)$ AH 1 0 1.00 $1.25(.99-1.58)$ $1.00(.87-1.34)$ AH 1 0 1.20 $0.90(.76-1.29)$ $1.20(.87-1.34)$ AH 1 0 1.20 $1.84(1.8-2.19)$ $1.90(.87-1.34)$ AH AH 0 $0.90(.71-1.29)$	ASIPMelanomadA BControlsCasesABnABnBnControlsABn00102065.725365 $Multivariate OR102065.725365Multivariate OR10090.990.76-1.29AH^{f}101207.75213AH^{f}101207.75214Multivariate OR3.161.4Multivariate OR0.99(0.76-1.29)Multivariate OR0.930.521.2AHf13Multivariate OR0.5213Multivariate OR0.521.4Multivariate OR0.521.2Multivariate OR0.521.4Multivariate OR0.521.4Multivariate OR0.521.4Multivariate OR0.521.4Multivariate OR0.521.4Multivariate OR0.520.520.52Multivariate OR$														
A B n Cases Cases <thcases< th=""> <thcases< th=""></thcases<></thcases<>	A B n Controls Cases A B n $\%$ n $\%$ 0 0 1020 65.7 253 65 1 1 1 366 23.6 91 22 AH^{f} 1 0 120 7.7 253 65 AH^{f} 1 0 120 7.7 252 13 AH^{f} 1 0 120 7.7 52 14 AH^{f} A 3.1 6 14 A_{f}	ASIP				Melan	loma ^d	ø	scce	BC	ç				
	A B n % n % 0 0 1020 65.7 253 65 0 0 1020 65.7 253 65 1 1 366 23.6 91 22 $Multivariate OR 366 23.6 91 22 Multivariate OR 0.99 (0.76-1.29) 0.99 (0.76-1.29) 13 AH^{\prime} 1 0 120 7.7 52 13 AH^{\prime} 1 0 120 7.7 52 14 0 0 48 3.1 6 14 Aritivariate OR 0.52 (0.21-1.29) Aritivariate OR 0.52 (0.21-1.29) $			Con	trols	Cas	ses		Cases	Ca	ses				
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	0 0 1020 65.7 253 65 Multivariate OR 1.00 1.00 22 1 1 366 23.6 91 22 AH ^f 1 0 120 7.7 52 13 AH ^f 1 0 120 7.7 52 13 0 0 48 3.1 6 1.4 Attivariate OR 3.1 52 1.4 Attivariate OR 3.1 52 1.4 Attivariate OR 3.1 52 1.4 Attivariate OR 0.52 (0.21-1.29) 53 53	Υ	в	п	%	п	%	u	%	u	%				
Multivariate OR 1.00 1.00 1.00 1.00 1 1 366 23.6 91 22.6 132 27.3 134 25.1 AH ^f 1 0 120 7.7 52 130 1.25 (0.90-1.58) 1.09 (0.87-1.38) AH ^f 1 0 120 7.7 52 13.0 52 10.7 48 9.0 Multivariate OR 7.7 52 13.0 52 10.7 48 9.0 0 0 120 7.7 52 13.0 52 10.7 48 9.0 Multivariate OR 1.68 (1.18-2.39) 1.54 (1.08-2.19) 1.52 (0.66-1.74) 1.22 (0.66-1.74) 0 0 48 3.1 6 1.6 1.52 (0.51-1.29) 1.52 (0.54-1.83) Article 0 0 1.68 (1.18-2.19) 1.54 (1.08-2.19) 1.52 (0.56-1.74) 1.55 (0.56-1.74) 1 1 0 0 1.68 (1.18-2.19) 0.43 (0.17-1.08) 1.00 (0.54-1.83) Article 1 6 1.5 0.43 (0.17-1.08)	Multivariate OR 1.00 1 1 366 23.6 91 22. AH ^f 1 0 120 7.7 52 13. AH ^f 1 0 120 7.7 52 13. 0 0 120 7.7 52 14. 0 0 48 3.1 6 1. Antivariate OR 3.1 6 1. A: rs4911414; B: rs1015362 A: rs4911414; B: rs1015362 0.52 (0.21-1.29)	0	0	1020	65.7	253	63	294	60.8	337	63.1				
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	1 1 1 366 23.6 91 22. AH ^f 1 0 Multivariate OR 0.99 (0.76-1.29) AH 1 0 120 7.7 52 13. Multivariate OR 1.68 (1.18-2.39) 1.68 (1.18-2.39) 0 0 48 3.1 6 1.4 Multivariate OR 3.1 6 1.4 A: rs4911414; B: rs1015362 A: rs49115362 0.52 (0.21-1.29)			Multiva	triate OR	1.0	00		1.00	1.0	00				
AH ^f I 0 120 0.99 (0.76-1.29) 1.25 (0.99-1.58) 1.09 (0.87-1.38) AH ^f I 0 120 7.7 52 13.0 52 10.7 48 9.0 Multivariate OR 1.68 (1.18-2.39) 1.54 (1.08-2.19) 1.52 (0.86-1.74) 1.22 (0.86-1.74) 0 0 48 3.1 6 1.6 6 1.2 1.5 Multivariate OR 0.52 (0.21-1.29) 0.43 (0.17-1.08) 1.00 (0.54-1.83) A: rs4911414; B: rs1015362 A: rs491144; B: rs1015362 0.43 (0.17-1.08) 1.00 (0.54-1.83)	AH ^f 1 0 0.99 (0.76-1.29) AH ^f 1 0 120 7.7 52 13 Multivariate OR 1.68 (1.18-2.39) 0 0 48 3.1 6 1.4 Multivariate OR 3.1 6 1.4 AH 3.1 6 1.4 AH 3.1 6 1.4 At state OR 0.52 (0.21-1.29) At rs4911414; Bt rs1015362	1	1	366	23.6	91	22.6	132	27.3	134	25.1				
AH ^f 1 0 120 7.7 52 13.0 52 10.7 48 9.0 Multivariate OR 1.68 (1.18–2.39) 1.54 (1.08–2.19) 1.22 (0.86–1.74) 0 0 48 3.1 6 1.2 1.52 (0.86–1.74) Multivariate OR 0.52 (0.21–1.29) 0.43 (0.17–1.08) 1.00 (0.54–1.83) 1.00 (0.54–1.83) A: rs4911414; B: rs1015362 A: rs4911414; B: rs1015362 0.43 (0.17–1.08) 1.00 (0.54–1.83)	AH ⁶ 1 0 120 7.7 52 13. Multivariate OR 1.68 (1.18–2.39) 0 0 48 3.1 6 1.4 Multivariate OR 0.52 (0.21–1.29) A: rs4911414; B: rs1015362			Multiva	rriate OR	0.99 (0.7	6-1.29)	1.25 ((0.99–1.58)	1.09 (0.8	87–1.38)				
Multivariate OR 1.68 (1.18-2.39) 1.54 (1.08-2.19) 1.22 (0.86-1.74) 0 0 48 3.1 6 1.6 6 1.2 1.5 2.8 Multivariate OR 0.52 (0.21-1.29) 0.43 (0.17-1.08) 1.00 (0.54-1.83) 1.00 (0.54-1.83) A: rs4911414; B: rs1015362 A A A A A A	Multivariate OR 1.68 (1.18-2.39) 0 0 48 3.1 6 1.4 Multivariate OR 0.52 (0.21-1.29) A: rs4911414; B: rs1015362	f 1	0	120	7.7	52	13.0	52	10.7	48	9.0				
0 0 48 3.1 6 1.6 6 1.2 1.5 2.8 Multivariate OR 0.52 (0.21–1.29) 0.43 (0.17–1.08) 1.00 (0.54–1.83) A: rs4911414; B: rs1015362	0 0 48 3.1 6 1. Multivariate OR 0.52 (0.21–1.29) A: rs4911414; B: rs1015362			Multiva	triate OR	1.68 (1.1	8-2.39)	1.54 (1.08–2.19)	1.22 (0.8	86-1.74)				
Multivariate OR 0.52 (0.21–1.29) 0.43 (0.17–1.08) 1.00 (0.54–1.83) A: rs4911414; B: rs1015362 A. rs4911414; B: rs1015362 A. rs4911414; B: rs1015362 A. rs4911414; B: rs1015362	Multivariate OR 0.52 (0.21–1.29) A: rs4911414; B: rs1015362	0	0	48	3.1	9	1.6	9	1.2	15	2.8				
A: rs4911414; B: rs1015362	A: rs4911414; B: rs1015362			Multive	triate OR	0.52 (0.2	21–1.29)	0.43 (I	0.17-1.08)	1.00 (0.5	54–1.83)				
				A: rs4911414; l	B: rs1015362										

Int J Cancer. Author manuscript; available in PMC 2010 August 15.

Nan et al.

 $^{d}\mathrm{TYR}$ -6895 G>A (rs1393350) was genotyped instead;

NIH-PA Author Manuscript NIH-P/

b p-value for global test for SCC is 0.007; c p-value for global test for BCC is 0.03;

 $d_{\rm p-value}$ for global test for melanoma is 0.008;

 $^{e}_{p}$ -value for global test for SCC is 0.004;

fAH means the ASIP haplotype carrying the rs4911414 variant allele [T] and the rs1015362 major allele [G].